NCT06386146RecruitingPhase 1/2
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- First submitted
- 23 Apr 2024
- Start date
- 24 Jul 2024
- Primary completion date
- Jan 2027
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Diseases
- Ovarian cancer
- NCT number
- NCT06386146
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 144
- From 24 Jul 2024 to the primary completion date, Jan 2027
- 13 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active infection requiring systemic treatment within 7 days.
- Active HBV or HCV.
- Any severe and/or uncontrolled medical conditions.
Lab values
- LVEF ≤50% assessed by ECHO or MUGA.
Other
- Active brain or spinal metastases or primary CNS tumor.
- QTcF \> 470 msec.
Who the study is looking for
- Written informed consent.
- Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
- ECOG performance status score of 0 or 1.
- Has been treated with at least one line of systemic therapy for that tumor type and stage.
- Have documentation of confirmed TP53 Y220C mutation.
- At least 1 measurable lesion per RECIST v1.1.
- Adequate hematological, renal and hepatic function and appropriate coagulation condition.
- Able to swallow and retain orally administered medication.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
| - Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
| - Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| - Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
| - Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
| - Coordinator of this site? Confirm its status | Canton | United States | Terminated |
| - Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Denver | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Lake Mary | United States | Terminated |
| - Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| - Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.